

RESEARCH ARTICLE

Open Access



Disorder-related risk factors for revision total hip arthroplasty after hip hemiarthroplasty in displaced femoral neck fracture patients: a nationwide population-based cohort study

Chun-Hao Tsai^{1,2,3}, Chih-Hsin Muo⁴, Chih-Hung Hung⁵, Tsung-Li Lin¹, Ta-li Wang¹, Yi-Chin Fong^{1,6,7} and Horng-Chaung Hsu^{1,2,3*}

Abstract

Background: The choice of primary hip hemiarthroplasty or total hip arthroplasty for displaced femoral neck fracture is still controversial. Revision hip arthroplasty not only increases risk and cost but also could result in worse outcome. Determining the risk factors for revision can help inform medical decision-making and aid in risk stratification of publicly reported outcomes. Therefore, we conducted a nationwide population-based study to identify the disease-related risk factors and construct a risk score nomogram to predict revision surgery.

Methods: Records of all 68,030 femoral neck fracture patients receiving partial hemiarthroplasty (HA) in 2000–2010, with no total hip arthroplasty (THA) or revision HA history, were collected from the National Health Insurance Research Database. Cox proportional hazard regression was used to estimate the risk of revision hip replacement (RHA). The score of each risk factor was the quotient of the regression coefficient of the variable by the regression coefficient for a 10-year increase in age. The predictive accuracy was tested using the area under the receiver operating characteristic curve (AUROC).

Results: The revision risk for hemiarthroplasty increased in male, those with schizophrenia and end-stage renal disease patients had 1.58-, 1.88-, and 1.74-fold revision HA risk (95 % confidence interval (CI) = 1.40–1.78, 1.26–2.79, and 1.29–2.34, respectively). In a predictive model, the cumulative risk score ranged from 0 to 13 with a 5.08 to 91.82 % 10-year predicted RHA risk. The percentage of AUROC for 10-year RHA risk in nomogram was 61.9 (95 % CI = 60.0–63.4).

Conclusions: Males, schizophrenia and end-stage renal disease patients have higher risk of revision surgery after hemiarthroplasty for femoral neck fracture.

Background

With the rapid development of the aging population, the total number of patients worldwide with hip fracture is predicted to rise to 6.26 million per year by 2050 [1]. Based on location, femoral neck fractures account for 45 to 53 % of hip fractures. The three major treatments for femoral neck fractures in clinical practice are internal

fixation, hemiarthroplasty (HA), and total hip arthroplasty (THA) [2, 3]. While internal fixation applies to undisplaced intracapsular fractures [4], the other two operative methods are advisable for displaced fractures in the elderly [5]. Since HA is a standardized surgical method that allows early weight bearing and recovery, it has become an established procedure with low risk of postoperative complications. Nonetheless, higher physical demands, even in older adults, occasionally necessitate conversion surgery to THA; this process likely to increase both the possible risks and the associated costs

* Correspondence: ritsai8615@gmail.com

¹Department of Orthopedic Surgery, China Medical University Hospital, #91 Hsueh-Shih Road, Taichung 404, Taiwan

²School of Medicine, China Medical University, Taichung, Taiwan
Full list of author information is available at the end of the article



[6, 7]. While debate continues on whether primary THA or HA is best for displaced femoral neck fracture [6, 8–10], the high complication rate of revision HA in comparison with THA is clearly known [11].

Therefore, it has become critical to determine the specific risk factors associated with the conversion of HA to revision hip replacement (RHA), to better assess the relative risks of each surgical procedure. The few studies of the risk factors associated with conversion to THA for hemiarthroplasty have identified several risk factors, such as younger age and male gender [12]. However, the weight of each risk factor has not yet been determined. Thus, we conducted a population-based, case-control study using the nationwide population-based database of a universal insurance program to evaluate the disease-related risk factors for conversion of HA to THA in femoral neck fracture in older adults.

Methods

Data source

The Taiwan Bureau of National Health Insurance (TBNHI) set up a single-payer National Health Insurance (NHI) Program on March 1, 1995. Almost all residents in Taiwan join this program. TBNHI commissioned the National Health Research Institutes to maintain the National Health Insurance Research Databases (NHIRDs) derived from the NHI program. We obtained from the NHIRDs data on all inpatient claims from 1996 to 2011. To be in compliance with the Personal Information Protection Act, the insurance information was de-identified and the scientists signed an agreement that they had no intention of obtaining personal information. This study was approved by the local institutional review board. The identification of disease was based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in the NHIRDs.

Study subjects and end-points

We collected adult patients with a new diagnosis of femoral neck fracture (ICD-9-CM code 820) who received partial hip arthroplasty (HA, ICD-9-operation code 81.52) in 2000–2010 ($N = 68,755$). The date of HA treatment was defined as the index date. Patients who had received total hip replacement (ICD-9-operation code 81.51, $n = 592$) or RHA (ICD-9-operation code 81.53, $n = 133$) before the index date were excluded. All study subjects were followed from the index date to the date of RHA treatment. Those without RHA treatment were followed until the date of withdrawal from the program or the end of 2011.

For the prediction model, we randomly assigned HA patients to either a derivation group or a validation group in a 3:1 ratio.

Risk factors

The risk factors included age, gender, and comorbidity. Comorbidities assessed (using ICD-9-CM codes) included diabetes (250), osteoporosis (733.0, V17.81, V82.81), rheumatoid arthritis (RA; 714), cancer (140–208), chronic obstructive pulmonary disease (COPD; 491,492, 496), previous osteoarthritis hip (715.5), end-stage renal disease (ESRD; 585), systemic lupus erythematosus (SLE; 710.0), ankylosing spondylitis (720), obesity (278.0), extrinsic asthma (493.0), human immunodeficiency virus (HIV; 042, V08, 795.71), atherosclerosis (440), smoking (350.1 and 649.0), psoriasis (696), viral hepatitis (070), depression (296.2, 296.3, 296.82, 300.4, 311), schizophrenia (295), heart failure (428), urinary tract infection (UTI; 599.0), ischemic heart disease (410–414), dementia (290, 294.1, and 331.0–331.2), and alcoholism (291, 303, 305.00–305.03, 790.3, V11.3). All comorbidities were defined before the index date.

Statistical analysis

Incidence of RHA and RHA-associated risk factors

The incidence of RHA (per 1000 person-years) was determined in patients by age, gender, and comorbidity. Cox proportional hazard regression was used to estimate the hazard ratios (HRs) and 95 % confidence interval (CI) of RHA and the RHA-associated risk factor. Multi-variable modeling was used, controlling for significant factors using crude Cox proportional hazard regression.

Prediction model

In future analysis, the prediction model was developed according to those risk factors identified as significant in this study. The score of each risk factor was the quotient of the regression coefficient of the variable by the regression coefficient for a 10-year increase in age. The cumulative risk score was the sum of the score of each risk factor. The area under the receiver operating characteristic curve (AUROC) of the nomogram was used to test the association of factors with RHA treatment using logistic regression. In future analysis, the patients were grouped into three groups based on risk scores: low (risk score 0–2), median (risk score 3–4), and high (risk score 5+). We plotted the cumulative incidence among risk score groups by Kaplan-Meier analysis in derivation and validation cohort. All statistical analyses were performed using the SAS software package SAS (version 9.4 for windows; SAS Institute, Cary, NC).

Results

All 68,030 femoral neck fracture patients who received hip hemiarthroplasty (HA) were selected for this study. Most patients were older than 70 years (80.8 %) and the mean age was 77.3 years (standard deviation = 9.26, Table 1). Most HA patients were female (65.0 vs. 35.0 %).

Table 1 Incidence and hazard ratio for revision hip replacement and associated risk factor

	<i>n</i>	(%)	Event no.	PY	Rate ^a	Crude HR (95 % CI)	Adjusted HR (95 % CI)
Total	68,030		1114	238,875	4.66		
Age, year							
20–29	53	(0.08)	9	260	34.57	30.9 (13.4–71.5)***	23.6 (10.2–54.7)***
30–39	158	(0.23)	11	832	13.23	12.0 (5.43–26.4)***	8.52 (3.85–18.9)***
40–49	499	(0.73)	25	2302	10.86	9.49 (4.93–18.3)***	6.90 (3.56–13.4)***
50–59	1862	(2.74)	63	7908	7.97	6.65–3.73 (11.9)***	5.48 (3.06–9.82)***
60–69	10,492	(15.4)	257	45,526	5.65	4.77 (2.79–8.17)***	4.35 (2.54–7.46)***
70–79	26,868	(39.5)	458	101,757	4.50	3.59 (2.11–6.12)***	3.38 (1.99–5.76)***
80–89	24,095	(35.4)	277	71,159	3.89	2.80 (1.64–4.80)***	2.73 (1.60–4.68)***
≥90	4003	(5.88)	14	9132	1.53	1.00	1.00
Mean (SD)	77.3	(9.26)					
Gender							
Women	44,241	(65.0)	614	163,685	3.75	1.00	1.00
Men	23,789	(35.0)	500	75,190	6.65	1.69 (1.50–1.90)***	1.58 (1.40–1.78)***
Comorbidity							
Diabetes							
No	51,877	(76.3)	861	191,518	4.50	1.00	
Yes	16,153	(23.7)	253	47,357	5.34	1.09 (0.95–1.26)	
Osteoporosis							
No	64,702	(95.1)	1057	228,211	4.63	1.00	
Yes	3328	(4.89)	57	10,664	5.35	1.11 (0.85–1.45)	
RA							
No	67,472	(99.2)	1099	236,796	4.64	1.00	
Yes	558	(0.82)	15	2079	7.21	1.57 (0.94–2.61)	
Cancer							
No	62,848	(92.4)	1038	226,145	4.59	1.00	
Yes	5182	(7.62)	76	12,730	5.97	1.14 (0.90–1.44)	
COPD							
No	60,853	(89.4)	1008	219,410	4.59	1.00	
Yes	7177	(10.6)	106	19,465	5.45	1.07 (0.88–1.31)	
ESRD							
No	66,073	(97.1)	1068	234,698	4.55	1.00	1.00
Yes	1957	(2.88)	46	4177	11.01	1.99 (1.48–2.68)***	1.74 (1.29–2.34)***
SLE							
No	67,963	(99.9)	1112	238,679	4.66	1.00	
Yes	67	(0.10)	2	196	10.19	2.03 (0.51–8.14)	
Ankylosing spondylitis							
No	64,346	(94.6)	1059	228,091	4.64	1.00	
Yes	3684	(5.42)	55	10,785	5.10	1.02 (0.78–1.34)	
Extrinsic asthma							
No	67,850	(99.7)	1112	238,299	4.67	1.00	
Yes	180	(0.26)	2	576	3.47	0.72 (0.18–2.89)	

Table 1 Incidence and hazard ratio for revision hip replacement and associated risk factor (Continued)

HIV							
No	68,022	(99.9)	1114	238,853	4.66	1.00	
Yes	8	(0.01)	0	22	0.00	--	
Atherosclerosis							
No	67,550	(99.3)	1106	237,521	4.66	1.00	
Yes	480	(0.71)	8	1355	5.91	1.17 (0.58–2.35)	
Psoriasis							
No	67,898	(99.8)	1112	238,505	4.66	1.00	
Yes	132	(0.19)	2	370	5.40	1.09 (0.27–4.36)	
Viral hepatitis							
No	66,212	(97.3)	1080	234,523	4.61	1.00	1.00
Yes	1818	(2.67)	34	4353	7.81	1.46 (1.04–2.06)*	1.30 (0.92–1.83)
Depression							
No	66,091	(97.2)	1081	232,874	4.64	1.00	
Yes	1939	(2.85)	33	6002	5.50	1.12 (0.79–1.59)	
Schizophrenia							
No	67,399	(99.1)	1088	236,468	4.60	1.00	1.00
Yes	631	(0.93)	26	2408	10.80	2.43 (1.65–3.58)***	1.88 (1.26–2.79)**
Heart failure							
No	62,500	(91.9)	1035	22,478	4.59	1.00	
Yes	5530	(8.13)	79	13,397	5.90	1.11 (0.89–1.40)	
UTI							
No	55,877	(82.1)	936	204,007	4.59	1.00	
Yes	12,153	(17.9)	178	34,869	5.10	1.2 (0.87–1.19)	
Ischemic heart disease							
No	55,681	(81.9)	915	203,038	4.51	1.00	
Yes	12,349	(81.9)	199	35,837	5.55	1.13 (0.97–1.32)	
Dementia							
No	65,633	(96.5)	1091	231,906	4.70	1.00	1.00
Yes	2397	(3.52)	23	6969	3.30	0.65 (0.43–0.98)*	0.71 (0.47–1.07)

PY person-years, HR hazard ratio, CI confidence interval, SD standard deviation, RA rheumatoid arthritis, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, SLE systemic lupus erythematosus, HIV human immunodeficiency virus, UTI urinary tract infection

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

^aPer 1000 person-years

The 10 most prevalent comorbidities in HA patients were diabetes (23.7 %), ischemic heart disease (18.2 %), UTI (17.9 %), COPD (10.6 %), heart failure (8.13 %), cancer (7.62 %), ankylosing spondylitis (5.42 %), osteoporosis (4.89 %), dementia (3.52 %), and ESRD (2.88 %).

After a cumulative 12-years follow-up, 1114 patients received RHA treatment, with an incidence of 4.66 per 1000 person-years (Table 1). In multivariable Cox proportional hazard regression, the RHA risk decreased with aging from 23.6 to 2.73 in those aged 20–29 to 80–89 years, respectively, compared with those aged ≥ 90 years (95 % CI = 10.2–54.7 and 1.60–4.68, respectively). Compared with women, men had a significantly higher RHA risk (HR = 1.58, 95 % CI = 1.40–1.78). RHA-associated risk factors for

the total cohort were schizophrenia (HR = 1.88, 95 % CI = 1.26–2.79) and ESRD (HR = 1.74, 95 % CI = 1.29–2.34).

Table 2 presents the distribution between derivation (75.0 %) and validation (25.0 %) cohort. There was no significant difference of age, gender, ESRD and schizophrenia between two groups. In derivation cohort, the risk score decreased one point with every 10 years of age increasing; for example, the risk score was 7 for patients aged 20–29 years, 6 for those 30–39 years, 5 for those 40–49 years, and so on (Table 3). The risk score was 2 for men, those with ESRD and schizophrenia patients. The percentage of AUROC for 10-year RHA risk in nomogram was 61.9 (95 % CI = 60.0–63.4). In the prediction model, the cumulative risk score ranged from

Table 2 Distribution of predictor between derivation and validation cohort

	Derivation cohort		Validation cohort		Chi-square <i>p</i> value
	<i>n</i>	%	<i>n</i>	%	
	N = 51021 (75.0 %)		N = 17009 (25.0 %)		
Age, year					0.98
20–29	40	0.08	13	0.08	
30–39	113	0.22	45	0.26	
40–49	371	0.73	128	0.75	
50–59	1388	2.72	474	2.79	
60–69	7878	15.4	2614	15.4	
70–79	20,177	39.6	6691	39.3	
80–89	18,047	35.4	6048	35.6	
≥ 90	3007	5.89	996	5.86	
Gender					0.97
Women	33,182	65.0	11,059	65.0	
Men	17,839	35.0	5959	35.0	
Comorbidity					
ESRD	1493	2.93	464	2.73	0.18
Schizophrenia	455	0.89	176	1.03	0.09

ESRD end-stage renal disease

0 to 13 with a 5.08 to 91.82 %10-year predicted RHA risk (Fig. 1).

Figure 2 presents cumulative incidence of RHA in different risk score groups. In derivation cohort, the cumulative incidences of RHA were 2.03, 3.85, and 6.06 % in low, median, and high after 10 years follow-up, respectively. In validation cohort, patients with higher risk score had highest cumulative incidence of RHA (6.24 %) and followed by median and low group (3.86 and 1.85 %).

Discussion

The current study revealed that the rate of RHA for primary HA for femoral neck fracture is 4.67 per 1000 person-years. Several risk factors, such as age, gender, ESRD, and schizophrenia, were identified. We also assessed the contribution of each factor to help clinicians predict future revision rate.

Traditionally, surgeons have preferred HA over THA because of concerns about the increased risk of complications of the more complex THA. However, more current data has showed no significant differences in the complication rates of patients undergoing HA versus THA [2, 9, 13, 14]. Moreover, the literature shows a lower risk of reoperation after THA compared with HA [6, 12, 14–16] and better functional outcomes for patients after THA versus HA [6, 8–10, 13, 14, 16, 17].

Table 3 Incidence and hazard ratio for revision hip replacement and associated risk factor in derivation cohort

	HR (95 % CI)	Regression coefficient	<i>p</i>	Risk score
Age, year				
20–29	40.4 (16.0–10.2)	3.700	< 0.0001	7
30–39	12.3 (4.85–31.0)	2.506	< 0.0001	6
40–49	8.40 (3.76–18.8)	2.128	< 0.0001	5
50–59	6.44 (3.14–12.2)	1.862	< 0.0001	4
60–69	4.92 (2.52–9.62)	1.593	< 0.0001	3
70–79	3.97 (2.05–7.71)	1.380	< 0.0001	2
80–89	3.38 (1.74–6.59)	1.218	0.0003	1
≥ 90	Ref.	0		0
Gender				
Women	Ref.	0		0
Men	1.57 (1.36–1.80)	0.449	< 0.0001	2
ESRD				
No	Ref.	0		0
Yes	1.72 (1.22–2.43)	0.542	0.002	2
Schizophrenia				
No	Ref.	0		0
Yes	1.84 (1.15–2.96)	0.611	0.01	2
Baseline disease-free probability				
At 10 years	96.89			
AUROC % (95 % CI)	61.9 (60.0–63.4)			

HR hazard ratio, CI confidence interval, AUROC the area under the receiver operating characteristic curve




Fig. 1 Nomograms for the prediction of the RHA risk




Fig. 2 Cumulative incidence for revision hip replacement among different risk score groups: low (risk score 0–2), median (risk score 3–4), and high (risk score 5+) in derivation (a) and validation (b) cohort

HA comes with considerable risk of reoperation with conversion to THA [18, 19]. Finite element mode study has proven that HA increases the biomechanical stresses on the acetabular bone that would result in migration of the head and destruction of the acetabulum [20]. Several studies found significant acetabular wear in up to 67 % of cases [21, 22], quantified at an average rate of 0.7 mm per year [22]. The inability to restore the femoral offset is also a factor [23], impairing the ability to balance tissue tension. However, THA is not suitable for every patient, including those with multiple morbidities or those with limited life expectancy [24]. The disadvantages of THA include greater blood loss and higher costs compared with HA [13]. Despite higher initial costs, the overall costs of THA are lower.

Young age and male gender are well-identified risk factors for revision HA surgery [12], but no literature has described schizophrenia or ESRD as risk factors for revision HA surgery. Schizophrenia has been associated with higher odds of perioperative blood transfusion, adverse events, and non-routine discharge following total joint arthroplasty (TJA) [25, 26] or spine surgery [27]. ESRD is also a risk factor for perioperative allogeneic blood transfusions [28], as it increased both mortality and the complication rate in TJR [29, 30].

Risk equations and risk functions have been widely applied for patient counseling, clinical diagnosis, risk stratification, treatment selection, and prognosis prediction; these have especially been useful in medical fields such as cardiovascular disease [31], hepatic disease [32, 33], and cancer [34, 35]. Most risk score systems used in orthopedic surgery are constructed according to the preoperative damage condition [36, 37], bony destruction [38], or postoperative fixation status [39]. In preoperative assessment of displaced femoral neck

fracture without complicated bony destruction, using demographic data and underlying comorbidity is an easy way to predict risk of revision. The nomogram of this study does not require complex calculations but allows surgeons to estimate the impact of demographic risk factors by easily adding the risk score. It helps facilitate clinician communication with patients about risk prediction and decision-making.

Our study has several limitations. First, we relied on NHIRDs to identify revisions and risk factors for revision HA surgery. Because the ICD-9 coding is representative of diseases, but not of the life style neither the physical finding. We are not able to analyze the population of smoker, alcohol use, and obesity because the insurance system only could code when the patients ask for medical treatment, which means the life style has threaten the health. Therefore, our data cannot show the risk of RHA in smoker, alcohol use, either BMI for obesity. However, smoke is a risk factor to infection [40], early failure, and revision surgery in total hip arthroplasty. Dislocation risk will be increased in alcoholism after total hip arthroplasty [41].

Second, the most common cause of revision hip replacement is loosening of the prosthesis (Table 4); however, there is no coding about primary surgery method or revision method. Therefore, we were not able to assess the surgical approach and type of prosthesis used (including retained stem, cemented, or noncemented prosthesis). Surgical approach would play a role in dislocation rate after hemiarthroplasty. Direct anterior [42, 43] or anterior-lateral approach has less dislocation rate that posterior approach [44, 45]. Both cemented and uncemented stem have good functional results in hip hemiarthroplasty for displaced femoral neck fractures [46]. But the uncemented hemiarthroplasty has high risk of postoperative

Table 4 Top ten reasons due to revision hip replacement (N = 1114)

Disease (ICD-9-CM)	Percentage
Mechanical complication of internal orthopedic device, implant, and graft (996.4)	62.6
Infection and inflammatory reaction due to internal prosthetic device, implant, and graft (996.6)	8.71
Other complications of internal (biological) (synthetic) prosthetic device, implant, and graft (996.7)	3.50
Shaft or unspecified part, closed (821.0)	2.69
Acquired deformities of hip (736.3)	2.60
Peritrochanteric fracture, closed (820.2)	2.60
Unspecified part of neck of femur, closed (820.8)	2.42
Osteoarthritis, localized, not specified whether primary or secondary (715.3)	1.97
Pyogenic arthritis (711.0)	1.53
Mechanical complication of other specified prosthetic device, implant, and graft (996.5)	1.44

periprosthetic femoral fractures to reoperation [47–50]. However, previous investigators have reported a reasonable correlation between administrative claims and the clinical record when evaluating causes and types of revision TJA procedures [13]. Third, our study was a retrospective cohort study rather than a prospective randomized trial. Besides, the life style pattern and physical characters of people vary in different countries. The medical insurance data result may be not as the same as other country due to different socioeconomic situations between nations. There may be some risk factors not significant in one population but may play an important role in others due to risk exposure cases number, especially in life style. Our result would not be representative of other country or population. However, the use of a population-based data set allows for the enrollment of a large number of patients and is highly representative of the risk factors of diseases found in a general population. This study reveals the importance of associated diseases affect the outcome in hip hemiarthroplasty for femoral neck fracture. In the future, we still need more cases from other population for comparison and meta-analysis to find out more risk factor or related disease.

Finally, our results are limited to risk factors for failures that occur within the 10 years after primary HA, and therefore, it is unclear whether the same or other risk factors are associated with longer term follow-up. However, the impact of patient comorbidities on the risk of revision after HA has important clinical and policy implications for the health care system. Finally, these HAs were for femoral neck fracture only; our study does not address the risk factors for HA for osteonecrosis of the femoral head.

Conclusions

In conclusion, to assess the future risk of revision, a risk score system was developed, based on patient demographics and comorbidities. Although the permissible degree of postoperative activity depends entirely on the general health status of each patient, the current result can help with arranging earlier rehabilitation and developing an appropriate follow-up program to prevent early complications.

Abbreviations

AUROC, area under the receiver operating characteristic curve; CI, confidence interval; HA, hemiarthroplasty; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NHI, National Health Insurance; RHA, revision hip arthroplasty; THA, total hip arthroplasty

Acknowledgements

We thank the National Health Research Institute in Taiwan for providing the related insurance claims data. This study was supported by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039 -005), and the China Medical University Hospital (Grant #1MS1).

Authors' contributions

All authors made substantive intellectual contributions to this study to qualify as authors. CHT and CHH designed the study. TLL and TIW collected the subjects' data. CHM performed the statistical analysis. An initial draft of the manuscript was written by CHT. HCH and YCF re-drafted parts of the manuscript and provided helpful advice on the final revision. All authors were involved in writing the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This study was approved by the Ethics Review Board of China Medical University (CMUH104-REC2-115).

Author details

¹Department of Orthopedic Surgery, China Medical University Hospital, #91 Hsueh-Shih Road, Taichung 404, Taiwan. ²School of Medicine, China Medical University, Taichung, Taiwan. ³Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan. ⁴Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. ⁵Tainan Municipal An-Nan Hospital-China Medical University, Tainan, Taiwan. ⁶China Medical University Beigang Hospital, Yunlin, Taiwan. ⁷School of Chinese Medicine, China Medical University, Taichung, Taiwan.

Received: 17 October 2015 Accepted: 19 May 2016

Published online: 08 June 2016

References

- Cooper C, Campion G, Melton 3rd LJ. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int*. 1992;2(6):285–9.
- Blomfeldt R, Tornkvist H, Eriksson K, Soderqvist A, Ponzer S, Tidermark J. A randomised controlled trial comparing bipolar hemiarthroplasty with total hip replacement for displaced intracapsular fractures of the femoral neck in elderly patients. *J Bone Joint Surg Br*. 2007;89(2):160–5.
- Florschutz AV, Langford JR, Haidukewych GJ, Koval KJ. Femoral neck fractures: current management. *J Orthop Trauma*. 2015;29(3):121–9.
- Bhandari M, Devereaux PJ, Swiontkowski MF, Tornetta 3rd P, Obrebsky W, Koval KJ, Nork S, Sprague S, Schemitsch EH, Guyatt GH. Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. *J Bone Joint Surg Am*. 2003;85-A(9):1673–81.

5. Bhandari M, Devereaux PJ, Torretta 3rd P, Swiontkowski MF, Berry DJ, Haidukewych G, Schemitsch EH, Hanson BP, Koval K, Dirschl D et al. Operative management of displaced femoral neck fractures in elderly patients. An international survey. *J Bone Joint Surg Am.* 2005;87(9):2122–30.
6. Hopley C, Stengel D, Ekkernkamp A, Wich M. Primary total hip arthroplasty versus hemiarthroplasty for displaced intracapsular hip fractures in older patients: systematic review. *BMJ.* 2010;340:c2332.
7. Figved W, Dybvik E, Frihagen F, Furnes O, Madsen JE, Havelin LI, Nordsletten L. Conversion from failed hemiarthroplasty to total hip arthroplasty: a Norwegian arthroplasty register analysis of 595 hips with previous femoral neck fractures. *Acta Orthop.* 2007;78(6):711–8.
8. Burgers PT, Van Geene AR, Van den Bekerom MP, Van Lieshout EM, Blom B, Aleem IS, Bhandari M, Poolman RW. Total hip arthroplasty versus hemiarthroplasty for displaced femoral neck fractures in the healthy elderly: a meta-analysis and systematic review of randomized trials. *Int Orthop.* 2012;36(8):1549–60.
9. Liao L, Zhao J, Su W, Ding X, Chen L, Luo S. A meta-analysis of total hip arthroplasty and hemiarthroplasty outcomes for displaced femoral neck fractures. *Arch Orthop Trauma Surg.* 2012;132(7):1021–9.
10. Goh SK, Samuel M, Su DH, Chan ES, Yeo SJ. Meta-analysis comparing total hip arthroplasty with hemiarthroplasty in the treatment of displaced neck of femur fracture. *J Arthroplasty.* 2009;24(3):400–6.
11. Sah AP, Estok 2nd DM. Dislocation rate after conversion from hip hemiarthroplasty to total hip arthroplasty. *J Bone Joint Surg Am.* 2008;90(3):506–16.
12. van den Bekerom MP, Sievelert IN, Bonke H, Raaymakers EL. The natural history of the hemiarthroplasty for displaced intracapsular femoral neck fractures. *Acta Orthop.* 2013;84(6):555–60.
13. SooHoo NF, Farnig E, Chambers L, Zmigmond DS, Lieberman JR. Comparison of complication rates between hemiarthroplasty and total hip arthroplasty for intracapsular hip fractures. *Orthopedics.* 2013;36(4):e384–9.
14. Zhao Y, Fu D, Chen K, Li G, Cai Z, Shi Y, Yin X. Outcome of hemiarthroplasty and total hip replacement for active elderly patients with displaced femoral neck fractures: a meta-analysis of 8 randomized clinical trials. *PLoS One.* 2014;9(5):e98071.
15. Ravikumar KJ, Marsh G. Internal fixation versus hemiarthroplasty versus total hip arthroplasty for displaced subcapital fractures of femur—13 year results of a prospective randomised study. *Injury.* 2000;31(10):793–7.
16. Avery PP, Baker RP, Walton MJ, Rooker JC, Squires B, Gargan MF, Bannister GC. Total hip replacement and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck: a seven- to ten-year follow-up report of a prospective randomised controlled trial. *J Bone Joint Surg Br.* 2011;93(8):1045–8.
17. Blomfeldt R, Tornkvist H, Ponzer S, Soderqvist A, Tidermark J. Displaced femoral neck fracture: comparison of primary total hip replacement with secondary replacement after failed internal fixation: a 2-year follow-up of 84 patients. *Acta Orthop.* 2006;77(4):638–43.
18. Dorr LD, Glousman R, Hoy AL, Vanis R, Chandler R. Treatment of femoral neck fractures with total hip replacement versus cemented and noncemented hemiarthroplasty. *J Arthroplasty.* 1986;1(1):21–8.
19. Keating JF, Grant A, Masson M, Scott NW, Forbes JF. Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. *J Bone Joint Surg Am.* 2006;88(2):249–60.
20. Ichihashi K, Imura S, Oomori H, Gesso H. Stress analysis on the acetabular side of bipolar hemiarthroplasty by the two-dimensional finite element method incorporating the boundary friction layer. *Nihon Seikeigeka Gakkai Zasshi.* 1994;68(11):939–52.
21. Bochner RM, Pellicci PM, Lyden JP. Bipolar hemiarthroplasty for fracture of the femoral neck. Clinical review with special emphasis on prosthetic motion. *J Bone Joint Surg Am.* 1988;70(7):1001–10.
22. Coleman SH, Bansal M, Cornell CN, Sculco TP. Failure of bipolar hemiarthroplasty: a retrospective review of 31 consecutive bipolar prostheses converted to total hip arthroplasty. *Am J Orthop (Belle Mead NJ).* 2001;30(4):313–9.
23. Abraham WD, Dimon 3rd JH. Leg length discrepancy in total hip arthroplasty. *Orthop Clin North Am.* 1992;23(2):201–9.
24. Browne JA, Pietrobbon R, Olson SA. Hip fracture outcomes: does surgeon or hospital volume really matter? *J Trauma.* 2009;66(3):809–14.
25. Bot AG, Menendez ME, Neuhaus V, Ring D. The influence of psychiatric comorbidity on perioperative outcomes after shoulder arthroplasty. *J Shoulder Elbow Surg.* 2014;23(4):519–27.
26. Buller LT, Best MJ, Klika AK, Barsoum WK. The influence of psychiatric comorbidity on perioperative outcomes following primary total hip and knee arthroplasty; a 17-year analysis of the National Hospital Discharge Survey database. *J Arthroplasty.* 2015;30(2):165–70.
27. Menendez ME, Neuhaus V, Bot AG, Ring D, Cha TD. Psychiatric disorders and major spine surgery: epidemiology and perioperative outcomes. *Spine (Phila Pa 1976).* 2014;39(2):E111–22.
28. Graves A, Yates P, Hofmann AO, Farmer S, Ferrari P. Predictors of perioperative blood transfusions in patients with chronic kidney disease undergoing elective knee and hip arthroplasty. *Nephrology (Carlton).* 2014;19(7):404–9.
29. Warth LC, Pugely AJ, Martin CT, Gao Y, Callaghan JJ. Total joint arthroplasty in patients with chronic renal disease: is it worth the risk? *J Arthroplasty.* 2015;30(9 Suppl):51–4.
30. Deegan BF, Richard RD, Bowen TR, Perkins RM, Graham JH, Foltzer MA. Impact of chronic kidney disease stage on lower-extremity arthroplasty. *Orthopedics.* 2014;37(7):e613–8.
31. Grimm JC, Magruder JT, Ohkuma R, Dungan SP, Hayes A, Vose AK, Orlando M, Sussman MS, Cameron DE, Whitman GJ. A novel risk score to predict dysphagia after cardiac surgery procedures. *Ann Thorac Surg.* 2015;100(2):568–74.
32. Kim BK, Kim SA, Park YN, Cheong JY, Kim HS, Park JY, Cho SW, Han KH, Chon CY, Moon YM et al. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. *Liver Int.* 2007;27(7):969–76.
33. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *J Clin Oncol.* 2010;28(14):2437–44.
34. Etzel CJ, Kachroo S, Liu M, D'Amelio A, Dong Q, Cote ML, Wenzlaff AS, Hong WK, Greisinger AJ, Schwartz AG et al. Development and validation of a lung cancer risk prediction model for African-Americans. *Cancer Prev Res (Phila).* 2008;1(4):255–65.
35. Dehing-Oberije C, Yu S, De Ruyscher D, Meersschout S, Van Beek K, Lievens Y, Van Meerbeeck J, De Neve W, Rao B, van der Weide H et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. *Int J Radiat Oncol Biol Phys.* 2009;74(2):355–62.
36. Helfet DL, Howey T, Sanders R, Johansen K. Limb salvage versus amputation. Preliminary results of the Mangled extremity severity score. *Clin Orthop Relat Res.* 1990;256:80–6.
37. Johansen K, Daines M, Howey T, Helfet D, Hansen Jr ST. Objective criteria accurately predict amputation following lower extremity trauma. *J Trauma.* 1990;30(5):568–72. discussion 572–563.
38. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. *Clin Orthop Relat Res.* 1989;249:256–64.
39. Lee SR, Kim ST, Yoon MG, Moon MS, Heo JH. The stability score of the intramedullary nailed intertrochanteric fractures: stability of nailed fracture and postoperative patient mobilization. *Clin Orthop Surg.* 2013;5(1):10–8.
40. Singh JA, Schleck C, Harmsen WS, Jacob AK, Warner DO, Lewallen DG. Current tobacco use is associated with higher rates of implant revision and deep infection after total hip or knee arthroplasty: a prospective cohort study. *BMC Med.* 2015;13(1):283.
41. Hedlundh U, Fredin H. Patient characteristics in dislocations after primary total hip arthroplasty. 60 patients compared with a control group. *Acta Orthop Scand.* 1995;66(3):225–8.
42. Baba T, Shitoto K, Kaneko K. Bipolar hemiarthroplasty for femoral neck fracture using the direct anterior approach. *World J Orthod.* 2013;4(2):85–9.
43. Langlois J, Delambre J, Klouche S, Faivre B, Hardy P. Direct anterior Hueter approach is a safe and effective approach to perform a bipolar hemiarthroplasty for femoral neck fracture: outcome in 82 patients. *Acta Orthop.* 2015;86(3):358–62.
44. Skoldenberg O, Ekman A, Salemyr M, Boden H. Reduced dislocation rate after hip arthroplasty for femoral neck fractures when changing from posterolateral to anterolateral approach. *Acta Orthop.* 2010;81(5):583–7.
45. Enocson A, Tidermark J, Tornkvist H, Lapidus LJ. Dislocation of hemiarthroplasty after femoral neck fracture: better outcome after the anterolateral approach in a prospective cohort study on 739 consecutive hips. *Acta Orthop.* 2008;79(2):211–7.
46. Figved W, Opland V, Frihagen F, Jervidalo T, Madsen JE, Nordsletten L. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures. *Clin Orthop Relat Res.* 2009;467(9):2426–35.

47. Chana R, Mansouri R, Jack C, Edwards MR, Singh R, Keller C, Khan F. The suitability of an uncemented hydroxyapatite coated (HAC) hip hemiarthroplasty stem for intra-capsular femoral neck fractures in osteoporotic elderly patients: the Metaphyseal-Diaphyseal Index, a solution to preventing intra-operative periprosthetic fracture. *J Orthop Surg Res.* 2011;6:59.
48. Taylor F, Wright M, Zhu M. Hemiarthroplasty of the hip with and without cement: a randomized clinical trial. *J Bone Joint Surg Am.* 2012;94(7):577–83.
49. Langslet E, Frihagen F, Opland V, Madsen JE, Nordsletten L, Figved W. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures: 5-year followup of a randomized trial. *Clin Orthop Relat Res.* 2014;472(4):1291–9.
50. Yli-Kyyny T, Sund R, Heinanen M, Venesmaa P, Kroger H. Cemented or uncemented hemiarthroplasty for the treatment of femoral neck fractures? *Acta Orthop.* 2014;85(1):49–53.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

